UNSPSC 51171957: Proglumide

This classification denotes an anti-ulcer agent with the molecular formula C18H26N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EPL8W5565D, chemically known as 2,5-diamino-5-oxopentanoic acid but generally known as proglumide, which bears US NIH Compound Identifier 738. European Medicines Agency schedules Proglumide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10078MIG.

UNSPSC 51171957 Proglumide is a Commodity code covering pharmaceutical drug products, and recent state and local activity shows solicitation for generic pharmaceuticals, over-the-counter products, and prescription-fulfillment services rather than the specific active pharmaceutical ingredient (API) the code nominally names. State and local buyers under this code include county criminal-justice departments procuring drug-testing services, state health and human services agencies managing pharmacy benefit programs, and multistate cooperative purchasing alliances serving state and local government facilities. The scope of work spans generic multi-source pharmaceutical distribution with specific National Drug Codes (NDCs), over-the-counter product supply, offender drug-screening services with immunoassay and confirmatory testing methodologies, and exploratory direct-to-manufacturer prescription contracting arrangements outside traditional pharmacy benefit manager channels.

Activity concentrates in Texas and Minnesota, with the Texas Health and Human Services Commission conducting market intelligence on direct-to-manufacturer pharmacy programs and Collin County Community Supervision and Corrections Department procuring offender specimen collection and drug testing services under RFP 2026-327 (due July 23, 2026, estimated value $600,000, two-year term with optional renewals to September 1, 2026). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across Minnesota, Oregon, and other participating jurisdictions, with awarded vendors required to supply through three authorized wholesalers and maintain compliance with cGMP, Drug Supply Chain Security Act, and FDA requirements. Both opportunities reflect state and local procurement moving beyond simple product purchasing toward managed service delivery, cost-control mechanisms, and supply-chain integration.